Latest & greatest articles for Ketamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Ketamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Ketamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Ketamine

41. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Full Text available with Trip Pro

Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Ketamine showed no cognitive or other benefit when given alongside ECT, but the study recruited fewer participants than planned and moderate benefits or harms cannot be excluded. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Ian M Anderson 1, * , Andrew

2017 NIHR HTA programme

42. Ketamine Analgesia for Acute Pain in the Emergency Department

Ketamine Analgesia for Acute Pain in the Emergency Department Emergency Medicine > Journal Club > Archive > April 2016 Toggle navigation April 2016 Ketamine Analgesia for Acute Pain in the Emergency Department Vignette It's two o'clock in the afternoon during a typical weekend TCC shift, when you get a page that a triage patient is coming to room 4. You look at the chart and see that it's a 45-year-old man who was riding his horse and got bucked off, landing on his left arm in an awkward (...) your attending about the IV lidocaine, which the patient says hasn't really helped his pain, but Dr. Cohn just shakes his head and sighs. You then ask about giving the patient low-dose ketamine for his pain, having recently listened to a podcast on the subject ( ). Dr. Cohn laughs in your face and turns his back on you. Later, he comes back and explains that while he admittedly hasn't read the literature on the subject, he isn't a big fan of replacing one addictive substance with another

2017 Washington University Emergency Medicine Journal Club

43. IM Ketamine for Prehospital Sedation of the Agitated Patient

IM Ketamine for Prehospital Sedation of the Agitated Patient Emergency Medicine > Journal Club > Archive > November 2016 Toggle navigation November 2016 IM Ketamine for Prehospital Sedation of the Agitated Patient Vignette You are working a night shift in EM-1 and have just started to catch up after signout, consisting of more than a few inebriated patients awaiting sobriety, when you hear commotion out in the hall. EMS and police are bringing in a large, screaming, Blailing, adult male patient (...) that might reduce the chances for injury of the patient and providers? How about something that is more rapid in onset than our old “5 and 2”? You remember hearing that ketamine is now being stocked on some ambulances for this purpose. When you wake up the next day after your shift you decide to look into the evidence behind prehospital ketamine for agitated patients. PICO Question Population: Adult patients with severe agitation requiring chemical sedation in the prehospital setting Intervention: IM

2017 Washington University Emergency Medicine Journal Club

44. Low-dose Ketamine for Acute Pain in the Emergency Department

Low-dose Ketamine for Acute Pain in the Emergency Department BestBets: Low-dose Ketamine for Acute Pain in the Emergency Department Low-dose Ketamine for Acute Pain in the Emergency Department Report By: Colby Duncan MD - Senior EM Resident Search checked by Brad Riley MD - EM Faculty Institution: Grand Rapids Medical Education Research Partners/Michigan State University Date Submitted: 15th July 2016 Date Completed: 11th February 2017 Last Modified: 11th February 2017 Status: Green (complete (...) ) Three Part Question [In ED patients with acute pain who do not respond to conventional therapies], is the [low-dose ketamine better than morphine] at [safely and effectively reducing pain scores]? Clinical Scenario A man aged 25 years presents to the ED with a closed fracture of the right humeral head. He has severe pain around the shoulder and is allergic to opioids. He is given intravenous ketorolac and midazolam. Unfortunately, the patient's pain does not improve. A colleague recommends the use

2017 BestBETS

45. Ketamine infusion for treatment-resistant bipolar depression

Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine infusion for treatment-resistant bipolar depression. Lansdale: HAYES, Inc. Healthcare Technology (...) Brief Publication. 2017 Authors' conclusions Health Problem: Bipolar disorder is a chronic illness characterized by alternating periods of profound depression and excessively elevated or irritable mood (mania). These episodes of extreme mood are interspersed by periods of relatively normal mood. Bipolar disorder is a severely impairing illness associated with unemployment, decreased productivity, and excess mortality. Technology Description: Ketamine therapy for bipolar disorder often involves

2017 Health Technology Assessment (HTA) Database.

46. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder

Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Health Problem: Treatment-resistant depression (TRD) is typically defined as depression that does not respond to at least 2 attempts at treatment of adequate duration with appropriate doses of antidepressants, but there is no official consensus definition. Posttraumatic stress disorder (PTSD) is an anxiety

2017 Health Technology Assessment (HTA) Database.

47. Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression

Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine as an adjunct (...) Description: Intravenous injection (IV) of ketamine hydrochloride as an adjunct to electroconvulsive therapy (ECT) is intended to reduce symptoms of depression more rapidly and to a greater extent than ECT alone in patients who have TRD. Controversy: Early evidence for the antidepressant effect of ketamine came from uncontrolled studies and TRD may have diverse causes and poor response rates that make it difficult to demonstrate whether or not ketamine treatment is effective. Key Questions: Does ketamine

2017 Health Technology Assessment (HTA) Database.

48. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Full Text available with Trip Pro

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) , Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Published: October, 2016 DOI: Abstract Background Both ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed

2016 Lancet

49. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression Full Text available with Trip Pro

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant (...) depression.In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks. Patients who discontinued double-blind treatment after at least 2 weeks for lack of efficacy could enter an optional 2-week open-label phase to receive ketamine with the same frequency as in the double-blind

2016 EvidenceUpdates Controlled trial quality: predicted high

50. Ketamine: stimulating antidepressant treatment? Full Text available with Trip Pro

Ketamine: stimulating antidepressant treatment? The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression (...) and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson and Johnson, Lundbeck, Lundbeck Institute, Pfizer, Servier, St. Jude Medical, Takeda University, Health Network Foundation, and Vancouver Coastal Health Research Institute. R.M. Investigator Janssen trials of esketamine; 'paid-for' ketamine clinic operated by Oxford Health NHS Foundation Trust - fees used to support the Trust. M.J.O. Consultant: Sunovion and Acadia

2016 BJPsych open

51. Proposal for practice guideline Low dose ketamine infusion in the management of chronic noncancer pain

Proposal for practice guideline Low dose ketamine infusion in the management of chronic noncancer pain Page 1 2016 Proposal for practice guideline Low dose ketamine infusion in the management of chronic non- cancer pain Contents Proposal for practice guideline 1 Low dose ketamine infusion in the management of chronic non-cancer pain 1 Contents 1 Executive Summary 2 Literature review 2 Literature summary: state of the science; state of the art 6 Proposal for best practice in low-dose ketamine (...) infusion in the management of patients with chronic non-cancer pain 6 Faculty of Pain Medicine Professional Documents 8 Appendix 1 11 Proposed mechanisms for the analgesic effect of ketamine 11 1. Inhibition of the N-methyl-D-aspartate (NMDA) -receptor 11 2. Intrinsic analgesic effect 11 3. Central antinociceptive effects 11 4 (a) Attentuation of acute opioid tolerance 11 4 (b) Prevention of opioid-induced hyperalgesia 11 5. Cytokine effects 11 6. Effect on depression (via BDNF) 11 Appendix 2 13

2016 Australian and New Zealand College of Anaesthetists

52. Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Full Text available with Trip Pro

Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Ketamine for treatment-resistant depression: recent developments and clinical applications | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ketamine for treatment-resistant depression: recent developments and clinical applications Article Text Clinical review Ketamine for treatment-resistant depression: recent developments

2016 Evidence-Based Mental Health

53. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial Full Text available with Trip Pro

Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial Low-dose ketamine has been used perioperatively for pain control and may be a useful adjunct to intravenous (IV) opioids in the control of acute pain in the emergency department (ED). The aim of this study was to determine the effectiveness of low-dose ketamine as an adjunct to morphine versus standard care (...) ) morphine and normal saline placebo (standard care group), 2) morphine and 0.15 mg/kg ketamine (group 1), or 3) morphine and 0.3 mg/kg ketamine (group 2). Participants were assessed at 30, 60, and 120 minutes after study medication administration and received rescue analgesia as needed to target a 50% reduction in pain. The primary outcome measure of pain relief, or pain intensity reduction, was derived using the NRS and calculated as the summed pain-intensity (SPID) difference over 2 hours. The amount

2015 EvidenceUpdates Controlled trial quality: predicted high

54. Ketamine in outpatient arthroscopic shoulder surgery: Effects on postoperative pain, hemodynamic stability and process times. Full Text available with Trip Pro

Ketamine in outpatient arthroscopic shoulder surgery: Effects on postoperative pain, hemodynamic stability and process times. Pain after arthroscopic shoulder surgery is often severe, and establishing a pain treatment regimen that does not delay discharge can be challenging. The reported ability of ketamine to prevent opioid-induced hyperalgesia has not been investigated in this particular setting.300 adult patients scheduled for shoulder arthroscopy under general anesthesia were recruited (...) for this observational clinical trial and were allotted to either receive 1mg/kg IV bolus of ketamine before surgery (ketamine group, KG) or to a control group (CG) without ketamine. NRS pain scores were obtained on the operative day and on postoperative days 1 and 2 and compared between groups. Secondary variables were blood pressure, heart rate, process times, satisfaction with the anesthetic and unwanted effects.Pain severity did not differ significantly between the groups at any time. Propofol injection rate

2015 Open medicine (Warsaw, Poland) Controlled trial quality: uncertain

55. Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines

Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One study failed

2014 Health Technology Assessment (HTA) Database.

56. Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness

Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Intravenous ketamine (...) for the treatment of pain syndromes: clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non

2014 Health Technology Assessment (HTA) Database.

57. Chronic pain: oral ketamine

Chronic pain: oral ketamine Chronic pain: or Chronic pain: oral k al ketamine etamine Evidence summary Published: 25 February 2014 nice.org.uk/guidance/esuom27 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in February 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Two small, short-term (...) , randomised, placebo-controlled trials and 1 small case series of n-of-1 trials provide no good quality evidence for the use of oral ketamine to treat chronic pain in adults. Only 1 phase I pilot study in young people was identified but this was too small and short-term to draw any firm conclusions about the efficacy and safety of oral ketamine for treating chronic pain in young people. In the studies that reported safety, oral ketamine was frequently associated with adverse effects that often resulted

2014 National Institute for Health and Clinical Excellence - Advice

58. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines

Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Major Depressive Disorder (MDD)Current evidence has consistently shown that IV ketamine may improve symptoms scored by the MADRS and HAM-D scoring tools at 24 hours in patients with MDD. However, identifying which

2014 Health Technology Assessment (HTA) Database.

59. Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department (Abstract)

Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department We compare the frequency of airway and respiratory adverse events leading to an intervention between propofol with 1:1 and 4:1 mixtures of propofol and ketamine (ketofol).We performed a randomized, double-blinded trial in which emergency department adults undergoing deep sedation received propofol, 1:1 propofol and ketamine, or 4:1 (...) propofol and ketamine. Our primary outcome was the frequency of airway and respiratory adverse events leading to an intervention. Other outcomes included sedation depth, efficacy, procedure and recovery time, patient satisfaction, pain, and procedural recall.Two hundred seventy-one subjects completed the trial, 90 receiving propofol, 85 receiving 1:1 propofol and ketamine, and 96 receiving 4:1 propofol and ketamine. Airway or respiratory adverse events leading to an intervention were similar between

2014 EvidenceUpdates Controlled trial quality: predicted high

60. Intravenous Ketamine for the Treatment of Pain Syndromes

Intravenous Ketamine for the Treatment of Pain Syndromes TITLE: Intravenous Ketamine for the Treatment of Pain Syndromes: Clinical Effectiveness DATE: 07 June 2013 RESEARCH QUESTIONS 1. What is the clinical effectiveness of intravenous (IV) ketamine for the treatment of recalcitrant chronic regional pain syndrome? 2. What is the clinical effectiveness of IV ketamine for the treatment of fibromyalgia? 3. What is the clinical effectiveness of IV ketamine for the treatment of reflex sympathetic (...) dystrophy? KEY MESSAGE One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness of IV ketamine for the treatment of fibromyalgia or reflex sympathetic dystrophy. METHODS

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review